Introduction: Numerous real-world studies have compared non-vitamin K antagonist oral
anticoagulants (NOACs) with vitamin K antagonists (VKAs) in patients with non-valvular …

Objective: To conduct a systematic literature review (SLR) and network meta-analysis (NMA)
of real-world studies comparing major bleeding risk among patients with non-valvular atrial …

Background. New oral anticoagulants (NOAC; rivaroxaban, dabigatran, apixaban) have
become available as an alternative to warfarin anticoagulation in non‐valvular atrial …

Objective To compare the efficacy, safety, and cost effectiveness of direct acting oral
anticoagulants (DOACs) for patients with atrial fibrillation. Design Systematic review …

Background and Purpose—This ARISTOPHANES study (Anticoagulants for Reduction in
Stroke: Observational Pooled Analysis on Health Outcomes and Experience of Patients) …

Aims To analyse the safety and efficacy of direct oral anticoagulants (DOACs) in real-world
studies including atrial fibrillation (AF) patients. Methods and results Systematic review and …

Purpose The findings from the observational studies comparing the effectiveness and safety
of non–vitamin K antagonist oral anticoagulants (NOACs) versus vitamin K antagonists …

Aims Observational studies have investigated the effectiveness and safety of direct oral
anticoagulants (DOACs) and vitamin K antagonists (VKAs) used in nonvalvular atrial …

Introduction: Several comparative real-world effectiveness studies on direct oral
anticoagulants (DOACs) have been conducted, but an overview of the available evidence …

Background: There is a plethora of real-world data on the safety and effectiveness of direct-
acting oral anticoagulants (DOACs); however, study heterogeneity has contributed to …